119136 Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem

119136
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité
      Click To Print This Page

      Aperçu

      Replacement Information

      Prix & Disponibilité

      RéférenceDisponibilité Conditionnement Qté Prix Quantité
      119136-10MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 10 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
          Catalogue Number119136
          Brand Family Calbiochem®
          Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
          References
          ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
          Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
          Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
          Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
          Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
          Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
          Product Information
          CAS number37739-05-2
          FormWhite solid
          Hill FormulaC₁₅H₂₀ClN₅O₄
          Chemical formulaC₁₅H₂₀ClN₅O₄
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetA1
          Primary Target K<sub>i</sub>2.3 nM
          Purity≥99% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Références bibliographiques

          Aperçu de la référence bibliographique
          Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
          Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
          Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
          Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
          Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
          Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision28-March-2013 JSW
          Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
          DescriptionAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number37739-05-2
          Chemical formulaC₁₅H₂₀ClN₅O₄
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityDMSO (100 mM) or H₂O (5 mM)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
          Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
          Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
          Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
          Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
          Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.